Extensive clinical evidence supports the wearable cardioverter defibrillator (WCD) as a therapy for protection from sudden cardiac death (SCD). The following research demonstrates the safe and effective use of the LifeVest for a wide range of patient conditions or situations.
Analysis of 11 studies, with almost 20,000 non-overlapping patients prescribed the WCD, which assessed the occurrence of sustained VT events and evaluated the use and effectiveness of WCDs among at-risk cardiac patients. Read more
Prospective registry of 2,000 US patients assessed the safety and efficacy of the WCD in real world setting. Read more
U.S. National WCD Experience
Retrospective study compared the long-term survival of more than 3,500 patients who wore the WCD to the patients who underwent first ICD implantation. Read more
German WCD Study
Retrospective study of more than 6,000 German patients evaluated safety and efficacy of the WCD in the German healthcare system. Read more
Post-MI WCD Study
Retrospective study examined the utility of providing the WCD to more than 8,400 patients determined to be at high risk of SCD during the post-MI waiting period. Read more
Retrospective observational parallel cohort study compared mortality outcomes of nearly 5,000 post-revascularization high-risk SCD patients. Read more
Multi-center clinical trial which led to FDA approval of the LifeVest. Read more
The wearable cardioverter defibrillator has been a focus of more than 100 scientific publications and presentations over the last several years. View additional publications
ZOLL is committed to research that advances the medical community’s understanding and management of cardiac patients. For more information or to get involved, email email@example.com.
Heart Failure Optimization (HF Opt)
International trial to document the improvement in ejection fraction (EF) during six months of optimizing medical therapy after a first hospitalization for a new heart failure diagnosis with EF less than 35%. Read more at clinicaltrials.gov.
A prospective registry to evaluate cardiac acoustic biomarkers in heart failure patients collected by a patient’s WCD. Read more at clinicaltrials.gov.
Benefit of µCor™ in Ambulatory Decompensated Heart Failure (BMAD HF)
A prospective, observational clinical trial that documents thoracic fluid index, ECG, body position, and activity measurements taken by a wearable sensor worn by heart failure patients. Read more at clinicaltrials.gov